371 related articles for article (PubMed ID: 30915652)
1. PANLAR consensus statement on biosimilars.
Kowalski SC; Benavides JA; Roa PAB; Galarza-Maldonado C; Caballero-Uribe CV; Soriano ER; Pineda C; Azevedo VF; Avila-Pedretti G; Babini AM; Cachafeiro-Vilar A; Cifuentes-Alvarado M; Cohen SB; Díaz PE; Soto LD; Encalada C; Garro B; Sariego IAG; Guibert-Toledano M; Rodriguez VJK; Lopez MEL; Ortega AP; Russell AS; Santos-Moreno P; Terán IS; Vargas A; Vásquez G; Xavier RM; Firedman DXX; Mysler E; Kay J
Clin Rheumatol; 2019 May; 38(5):1485-1496. PubMed ID: 30915652
[TBL] [Abstract][Full Text] [Related]
2. Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey.
Castañeda-Hernández G; Sandoval H; Coindreau J; Rodriguez-Davison LF; Pineda C
Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1035-1044. PubMed ID: 31148288
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America.
de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R
J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars in rheumatology: current perspectives and lessons learnt.
Dörner T; Kay J
Nat Rev Rheumatol; 2015 Dec; 11(12):713-24. PubMed ID: 26282080
[TBL] [Abstract][Full Text] [Related]
5. Practical Guidance on Biosimilars, With a Focus on Latin America: What Do Rheumatologists Need to Know?
Azevedo VF; Babini A; Caballero-Uribe CV; Castañeda-Hernández G; Borlenghi C; Jones HE
J Clin Rheumatol; 2019 Mar; 25(2):91-100. PubMed ID: 30059414
[TBL] [Abstract][Full Text] [Related]
6. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.
Kay J; Schoels MM; Dörner T; Emery P; Kvien TK; Smolen JS; Breedveld FC;
Ann Rheum Dis; 2018 Feb; 77(2):165-174. PubMed ID: 28866648
[TBL] [Abstract][Full Text] [Related]
7. Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.
Uhlig T; Goll GL
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv49-iv62. PubMed ID: 28903542
[TBL] [Abstract][Full Text] [Related]
8. [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology].
Schreiber S; Luger T; Mittendorf T; Mrowietz U; Müller-Ladner U; Schröder J; Stallmach A; Bokemeyer B
Dtsch Med Wochenschr; 2014 Nov; 139(47):2399-404. PubMed ID: 25390629
[TBL] [Abstract][Full Text] [Related]
9. The changing landscape of biosimilars in rheumatology.
Dörner T; Strand V; Cornes P; Gonçalves J; Gulácsi L; Kay J; Kvien TK; Smolen J; Tanaka Y; Burmester GR
Ann Rheum Dis; 2016 Jun; 75(6):974-82. PubMed ID: 26964144
[TBL] [Abstract][Full Text] [Related]
10. The Portuguese Society of Rheumatology position paper on the use of biosimilars - 2017 update.
Araújo FC; Sepriano A; Teixeira F; Jesus D; Rocha TM; Martins P; Tenazinha C; Cordeiro A; Mourão AF; Silva C; Vaz C; Duarte C; Ponte C; Dos Santos FP; Canhão H; Santos H; Pimentão JB; da Silva JC; Pereira J; da Silva JAP; Miranda LC; Oliveira M; Saavedra MJ; Gonçalves P; Falcão S; Capela S; Fonseca JE
Acta Reumatol Port; 2017; 42(3):219-228. PubMed ID: 28894080
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI).
Schaeverbeke T; Pham T; Richez C; Wendling D
Joint Bone Spine; 2018 Jul; 85(4):399-402. PubMed ID: 29574143
[No Abstract] [Full Text] [Related]
12. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
Jahnz-Rozyk K; Wiesik-Szewczyk E;
Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor necrosis factor biosimilars and intended copies in rheumatology: Perspective from the Asia Pacific region.
Rath PD; Chen DY; Gu J; Lee VWY; Al Ani NA; Shirazy K; Llamado L
Int J Rheum Dis; 2019 Jan; 22(1):9-24. PubMed ID: 30338644
[TBL] [Abstract][Full Text] [Related]
14. Report on the Second PANLAR Review Course in Rheumatology: Biosimilars Update.
Caballero-Uribe CV; Azevedo VF; Soriano ER; Pineda C; Galarza-Maldonado C; Kos IA; Jimenez OC
J Clin Rheumatol; 2020 Jan; 26(1):33-36. PubMed ID: 30273265
[No Abstract] [Full Text] [Related]
15. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
[TBL] [Abstract][Full Text] [Related]
16. [Revised version of the statement by the DGRh on biosimilars-update 2017].
Braun J; Lorenz HM; Müller-Ladner U; Schneider M; Schulze-Koops H; Specker C; Strangfeld A; Wagner U; Dörner T
Z Rheumatol; 2018 Feb; 77(1):81-90. PubMed ID: 29383440
[TBL] [Abstract][Full Text] [Related]
17. Current state of biosimilars in Mexico: The position of the Mexican College of Rheumatology, 2016.
Xibille D; Carrillo S; Huerta-Sil G; Hernández R; Limón L; Olvera-Soto G; Jara-Quezada LJ; Esquivel A; Pérez-Rodríguez M
Reumatol Clin (Engl Ed); 2018; 14(3):127-136. PubMed ID: 28807650
[TBL] [Abstract][Full Text] [Related]
18. Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective.
Teran E; Gomez H; Hannois D; Lema M; Mantilla W; Rico-Restrepo M; McElwee E; Castro Sanchez N; Valdivieso N; Espinoza MA
Lancet Oncol; 2022 Jul; 23(7):e348-e358. PubMed ID: 35772466
[TBL] [Abstract][Full Text] [Related]
19. The Regulation of Biosimilars in Latin America.
Garcia R; Araujo DV
Curr Rheumatol Rep; 2016 Mar; 18(3):16. PubMed ID: 26951254
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in rheumatology.
Araújo FC; Gonçalves J; Fonseca JE
Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
